Why is AbbVie suing the U.S. Department of Health and Human Services?

AbbVie sued HHS to challenge a decision by the Centers for Medicare & Medicaid Services to impose price controls on Botox, which the company argues is an exempt plasma-derived product.

What is AbbVie's main argument against the price controls on Botox?

AbbVie's main argument is that Botox is a plasma-derived product specifically excluded from price controls under the Inflation Reduction Act of 2022, and that the controls violate its constitutional rights.

How much revenue does Botox account for AbbVie?

Botox accounted for just over 10% of AbbVie's $61.16 billion in revenue last year.

Home / Business and Economy / AbbVie Sues HHS Over Botox Price Controls

AbbVie Sues HHS Over Botox Price Controls

12 Feb

•

Summary

AbbVie filed suit challenging Medicare's decision to impose price controls on Botox.
The drugmaker argues Botox is a plasma-derived product exempt from price controls.
AbbVie claims the price controls violate constitutional rights and seek to end them.

AbbVie Sues HHS Over Botox Price Controls

AbbVie initiated legal action against the U.S. Department of Health and Human Services on Wednesday, contesting a Centers for Medicare & Medicaid Services decision to apply price controls to Botox.

The complaint, filed in a Washington, D.C. federal court, asserts that Congress explicitly excluded certain Medicare-covered medications, including plasma-derived products like Botox, from price controls when passing the Inflation Reduction Act of 2022.